Table 1.
Demographic and clinical characteristics of all study subjects who underwent the first prostate biopsy
| Total | No cancer | Cancer | P value | |
|---|---|---|---|---|
| N, 140 | N, 77 (55%) | N, 63 (45%) | – | |
| Age, yr | 69.0 (10.0) | 67.0 (9.0) | 72.0 (10.0) | 0.001 |
| tPSA, ng/mL | 6.93 (6.05) | 6.45 (3.8) | 8.18 (15.3) | 0.010 |
| fPSA | 1.03 (0.92) | 0.92 (0.8) | 1.07 (1.4) | 0.160 |
| %fPSA | 14.55 (9.29) | 17.13 (8.0) | 11.16 (9.0) | 0.003 |
| p2PSA, pg/mL | 19.18 (30.97) | 15.54 (16.7) | 31.06 (58.6) | < 0.001 |
| %p2PSA | 2.02 (2.21) | 1.57 (1.5) | 2.83 (2.6) | < 0.001 |
| PHI | 45.90 (82.72) | 39.54 (38.0) | 91.18 (147.9) | < 0.001 |
| Positive core number | – | – | 5.0 (7.0) | – |
| Number (percentage) | ||||
| GS 6% | – | – | 15 (23.8%) | – |
| GS 7 | 18 (28.6%) | – | ||
| GS ≥ 8 | 30 (47.6%) | – | ||
Data are shown as median (interquartile range), or number (%)
PSA, prostate-specific antigen; tPSA, total PSA; fPSA, free PSA; p2PSA, [2]proPSA, PHI, prostate health index; GS, Gleason score
P value to be statiscally significant with bolditalics